ProCE Banner Activity

ART-PRO: 48-Week Results of DTG + 3TC for Maintenance of Virologic Suppression in Patients With Historical 3TC Resistance

Slideset Download
Conference Coverage
This proof-of-concept study demonstrated that switching to DTG + 3TC maintained virologic control in INSTI-naive patients with historical 3TC resistance but no 3TC resistance-associated mutations in proviral DNA at baseline according to Sanger sequencing.

Released: November 16, 2019

Expiration: November 14, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare